{"domain":"terremotobio.com","status":"valid","tier":"listed","authority":46,"verified":false,"title":"Terremoto","summary":"Generated by All in One SEO v5.0.2.1, this is an llms.txt file, used by LLMs to index the site.","country":null,"country_source":"cdn","publisher_country":null,"publisher_country_source":null,"hosting_country":null,"llms_txt":"https://terremotobio.com/llms.txt","llms_full_txt":null,"last_checked":"2026-10-24T01:55:22.136Z","agent_terms":null,"categories":["marketing","science-research","healthcare"],"capabilities":[],"inferred_tags":["akt1 inhibitor","oncology drug development","hereditary hemorrhagic telangiectasia","biotech press releases","fda fast track"],"audience":"mixed","agent_uses":["search_content"],"language":"en","platform_generated":false,"agent_summary":"Terremoto Biosciences, a biotech developing selective AKT1 inhibitors for oncology and HHT; the excerpt lists press releases on financing, leadership and FDA de","llms_txt_cached":"https://agentwebmap.com/v1/domain/terremotobio.com/llms.txt","agentic":"informational","section_keys":["pages","portfolio-categories","portfolio-items","posts","sitemaps"],"section_partial":false,"section_indexed_at":"2026-10-24T01:55:26.481Z"}